Related references
Note: Only part of the references are listed.Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice
Yuka Hayakawa et al.
INVESTIGATIONAL NEW DRUGS (2022)
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
Ann-Lii Cheng et al.
JOURNAL OF HEPATOLOGY (2022)
Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma
Kazuki Maesaka et al.
HEPATOLOGY RESEARCH (2022)
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice
Takaaki Tanaka et al.
HEPATOLOGY RESEARCH (2022)
Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma
Karla A. Lee et al.
NATURE MEDICINE (2022)
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
Josep M. Llovet et al.
HEPATOLOGY (2021)
Cancer and the Microbiome-Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy
Vyara Matson et al.
GASTROENTEROLOGY (2021)
Systemic treatment of hepatocellular carcinoma: An EASL position paper
Jordi Bruix et al.
JOURNAL OF HEPATOLOGY (2021)
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response
Christine N. Spencer et al.
SCIENCE (2021)
The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression
Nobuaki Ochi et al.
EUROPEAN JOURNAL OF CANCER (2021)
Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update
Masatoshi Kudo et al.
LIVER CANCER (2021)
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
Alessio Cortellini et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
The association between CD8+tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis
Feng Li et al.
ECLINICALMEDICINE (2021)
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma
Petros Fessas et al.
LIVER CANCER (2021)
Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials
M. Chalabi et al.
ANNALS OF ONCOLOGY (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab
Ashley M. Hopkins et al.
EUROPEAN UROLOGY (2020)
Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy
Lukas F. Mager et al.
SCIENCE (2020)
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
John D. Gordan et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis
Atsushi Hiraoka et al.
LIVER CANCER (2019)
A defined commensal consortium elicits CD8 T cells and anti-cancer immunity
Takeshi Tanoue et al.
NATURE (2019)
Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis
Steve Lu et al.
JAMA ONCOLOGY (2019)
Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with updates hepatocellular carcinoma
Yi Zheng et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer
David J. Pinato et al.
JAMA ONCOLOGY (2019)
AASLD guidelines for the treatment of hepatocellular carcinoma
Julie K. Heimbach et al.
HEPATOLOGY (2018)
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
V. Gopalakrishnan et al.
SCIENCE (2018)
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Bertrand Routy et al.
SCIENCE (2018)
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
L. Derosa et al.
ANNALS OF ONCOLOGY (2018)
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
Jorge A. Marrero et al.
HEPATOLOGY (2018)
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Vyara Matson et al.
SCIENCE (2018)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Antibiotic-Induced Changes in the Intestinal Microbiota and Disease
Simone Becattini et al.
TRENDS IN MOLECULAR MEDICINE (2016)
Programmed death ligand 1 as an indicator of pre-existing adaptive immune responses in human hepatocellular carcinoma
Qian-Kun Xie et al.
ONCOIMMUNOLOGY (2016)
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach-The ALBI Grade
Philip J. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Marie Vetizou et al.
SCIENCE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Riccardo Lencioni et al.
SEMINARS IN LIVER DISEASE (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)